Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
357336-20-0
Molecular formula
C11H20N2O2
Molecular weight
212.29 g/mol
Drug class
Antiseizure medicine (ASM)high-affinity synaptic vesicle protein 2A (SV2A) ligand
Mechanism of action
The precise mechanism by which brivaracetam exerts its anticonvulsant effect is not known. It binds with high and selective affinity to synaptic vesicle protein 2A (SV2A) in the brain; this binding may contribute to its antiseizure activity and should not be presented as a fully established causal mechanism.
Indications / reported uses
Treatment of partial-onset (focal) seizures in patients aged 1 month and older; may be used as monotherapy or adjunctive therapy according to the specific product label and jurisdiction
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Brivaracetam PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Brivaracetam Permitted Daily Exposure (PDE) report (the Brivaracetam PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Brivaracetam Occupational Exposure Limit (OEL) report (the Brivaracetam OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.